Browsing Tag
biotech M&A
5 posts
Vertex (VRTX) to enter endocrine diseases with $10bn Crinetics acquisition, targets $5bn peak revenue by 2029
Vertex Pharmaceuticals to acquire Crinetics for $10 billion at 102% premium, largest deal in VRTX history. Read the full analysis.
Hanmi Pharmaceutical to acquire Aptose Biosciences in C$2.41-per-share deal with 28% premium
Find out how Hanmi Pharmaceutical’s acquisition of Aptose Biosciences is reshaping the AML treatment landscape today!
Argent BioPharma (ASX: RGT) acquires AusCann assets in $15m deal — can it unlock U.S. listing potential?
Argent BioPharma acquires AusCann assets in a $15M deal to expand its clinical pipeline, strengthen EU infrastructure, and advance toward a U.S. listing.
CureVac stock surges as BioNTech announces strategic mRNA-focused acquisition
BioNTech acquires CureVac in a $1.25B all-stock deal to expand its mRNA cancer pipeline. Includes stock insights, premium terms, and investor sentiment.
Scinai Immunotherapeutics secures Italian approval to advance Pincell acquisition and PC111 development
Scinai Immunotherapeutics receives Italian Golden Power clearance for proposed Pincell buyout, moving closer to advancing PC111 monoclonal antibody program.